Wave Life Sciences Ltd. (WVE) just dropped some intriguing data that might make you rethink how obesity drugs could work. On Monday, the biotech company shared interim results from its INLIGHT trial testing WVE-007, an experimental treatment that takes a different approach to weight management by targeting something called INHBE using the company's proprietary SpiNA design technology.

Here's what makes this interesting: a single 240 mg subcutaneous dose didn't just reduce weight in a general sense. It specifically slashed visceral fat—the dangerous kind that wraps around your organs—by 9.4% at the three-month mark. Total body fat dropped by 4.5% (about 3.5 pounds), and here's the kicker: lean mass actually increased by 3.2% (roughly 4 pounds). That's muscle you're gaining, not losing.

The INLIGHT trial enrolled otherwise healthy people living with overweight or obesity, with BMI between 28 and 35 kg/m2 and HbA1c below 5.9. Importantly, participants weren't asked to change their diet or exercise habits. This is just the drug working on its own. More than 100 individuals have been enrolled so far.

The latest update covers 32 people who received the single 240 mg dose, with an average baseline BMI of around 32 kg/m2. The placebo group saw essentially no meaningful changes: visceral fat down just 0.2%, total body fat down 0.5%, and lean mass up 2.3%.

What the Experts Think

"The data indicate meaningful reductions in body fat, particularly targeting harmful visceral fat, while preserving lean mass," said Dr. Angela Fitch, co-founder and Chief Medical Officer at knownwell, former co-director of the Massachusetts General Hospital Weight Center, Harvard Medical School faculty, and former president of the Obesity Medicine Association.

When researchers adjusted for the placebo effect, the numbers held up impressively: 9.2% visceral fat reduction, 4.0% total fat mass reduction, 0.9% lean mass increase, and just 0.9% total mass decrease. The fact that total body weight barely budged makes sense when you consider that fat loss was largely offset by muscle gain.

How It Works and Dosing Potential

WVE-007 works by knocking down serum Activin E levels. The drug achieved maximum reductions of 78% at 43 days after a single dose, and mean reductions stayed above 75% through at least Day 85. That kind of durability suggests this could be a once or twice-yearly treatment rather than a daily pill or weekly injection.

Safety-wise, the drug has performed well across doses up to 600 mg. There were no discontinuations and no severe or serious treatment-emergent adverse events. Everything reported was mild to moderate, with all treatment-related events being mild.

What Comes Next

The INLIGHT trial continues with three cohorts now fully dosed: 240 mg (32 participants), 400 mg (32 participants), and 600 mg (32 participants).

Wave has laid out a clear timeline for upcoming data releases. In Q1 2026, expect six-month follow-up data from the 240 mg cohort and three-month data from the 400 mg cohort. Q2 2026 should bring six-month results from the 400 mg group and three-month data from the 600 mg cohort.

The company is already planning Phase 2 trials with multiple strategies in mind. They'll test WVE-007 as a standalone treatment, as an add-on therapy combined with incretin drugs (think medications like Ozempic and Wegovy) in populations with higher BMI and related health complications, and as maintenance therapy after incretin treatment.

The market clearly liked what it heard. Wave Life Sciences shares surged 133.78% to $17.51 on Monday, hitting a new 52-week high.